Abstract
The past decade has seen innumerable challenges and advances in diabetes, and much remains to be done. I am pleased to say that our journal is playing an increasingly important role in advancing the scientific literature and the field itself. Diabetes Technology & Therapeutics (DTT) saw a significant improvement in all metrics for the journal. For example, the number of submissions to the journal increased more than twofold. In the last ten years other metrics have shown dramatic growth such as the number of downloads 73%, and the number of citations 67%. In the past 5 years, articles published as Open Access have increased by 22%. I am pleased to report that now the journal has an impact factor of 4.48, which represents a significant increase due to your continued support and the number of high-quality original articles being published in the journal. Unfortunately, this has led to an increase in the rejection rate for submitted manuscripts.
I'm grateful for our close collaboration for the past seven years with Advanced Technologies & Treatments for Diabetes (ATTD), a conference held in February annually in Europe and my close friendship with Moshe Phillip and Tadej Battelino, the organizers of ATTD. DTT is the official journal for ATTD which sponsors the well-read ATTD Yearbook and all the abstracts presented at the meeting in an online supplement. The special supplement includes ATTD Yearbook, an invaluable resource for the most impactful articles published from July 2018 to June 2019. Almost all of the Yearbook chapters that include valuable commentaries are written by the leading experts in the field of diabetes and endocrinology. Last year's Yearbook has had more than 26,000 downloads since February 2019, and the meeting abstracts have been downloaded more than 8,300 times worldwide. I hope and expect that this collaboration will only flourish in the coming years. The Yearbook in DTT is a vital source for manuscripts that can be searched on PubMed, Google, and other search engines.
I am thankful for a great editorial team that continues to support the journal on a daily basis. Senior Editors Jay Skyler, Irl Hirsch, and Roy Beck provide important guidance on the direction of the journal. The addition of Jessica Castle as Associate Editor and David Rodbard as Deputy Editor have been of tremendous help to the journal. I want to take this opportunity again to sincerely thank Drs. Ananda and Rita Basu, who helped the journal for nearly five years as Associate Editors before they retired. As is traditional, we will be changing some of the members of the editorial board in 2020.
Finally, prevalence of diabetes continues to increase globally both for T1D and T2D and there is a lack of adequately trained providers. Impending healthcare reforms in the US are on the horizon. Hence an increased effort toward providing care through digital platforms (telemedicine, decision support systems, developing automation and algorithms for guiding patients in real-life) will be needed. An upcoming pre-meeting workshop on digital medicine during the ATTD conference in Madrid, Spain in February 2020 will address some of these challenges.
I am always looking forward to your expert participation that includes manuscript submissions and critical reviews. I wish you all the best for 2020.